The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Open accessAbstract
MicroRNAs are short non-coding RNAs expressed in different tissue and cell types that suppress the expression of target genes. As such, microRNAs are critical cogs in numerous biological processes, and dysregulated microRNA expression is correlated with many human diseases. Certain microRNAs, called oncomiRs, play a causal role in the onset and maintenance of cancer when overexpressed. Tumours that depend on these microRNAs are said to display oncomiR addiction. Some of the most effective anticancer therapies target oncogenes such as EGFR and HER2; similarly, inhibition of oncomiRs using antisense oligomers (that is, antimiRs) is an evolving therapeutic strategy. However, the in vivo efficacy of current antimiR technologies is hindered by physiological and cellular barriers to delivery into targeted cells. Here we introduce a novel antimiR delivery platform that targets the acidic tumour microenvironment, evades systemic clearance by the liver, and facilitates cell entry via a non-endocytic pathway. We find that the attachment of peptide nucleic acid antimiRs to a peptide with a low pH-induced transmembrane structure (pHLIP) produces a novel construct that could target the tumour microenvironment, transport antimiRs across plasma membranes under acidic conditions such as those found in solid tumours (pH approximately 6), and effectively inhibit the miR-155 oncomiR in a mouse model of lymphoma. This study introduces a new model for using antimiRs as anti-cancer drugs, which can have broad impacts on the field of targeted drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Self-citationSilencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
(1989) · PubMed · Cited by 3,343
Dweep, H., Sticht, C., Pandey, P., & Gretz, N. (2011) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2011.05.002 · Cited by 1,696
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 1,073
Self-citationPre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice
Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., & Croce, C. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602266103 · Cited by 951
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
Self-citationSilencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
A viral microRNA functions as an orthologue of cellular miR-155
Gottwein, E., Mukherjee, N., Sachse, C., Frenzel, C., Majoros, W. H., Chi, J.-T. A., Braich, R., Manoharan, M., Soutschek, J., Ohler, U., et al. (2007) · Nature · doi:10.1038/nature05992 · Cited by 566
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology
DeVita, V. T., Lawrence, T. S., & Rosenberg, S. A. (2011) · Cited by 539
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I. A., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 497
Self-citationSolid‐Phase synthesis of peptide nucleic acids
Christensen, L., Fitzpatrick, R., Gildea, B., Petersen, K. H., Hansen, H. F., Koch, T., Egholm, M., Buchardt, O., Nielsen, P. E., Coull, J., et al. (1995) · Journal of Peptide Science · doi:10.1002/psc.310010304 · Cited by 337
Monitoring disulfide bond formation in the eukaryotic cytosol
Østergaard, H., Tachibana, C., & Winther, J. R. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200402120 · Cited by 333
Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone
Nielsen, P. E., Egholm, M., & Buchardt, O. (1994) · Bioconjugate Chemistry · doi:10.1021/bc00025a001 · Cited by 320
Transcriptome-wide miR-155 Binding Map Reveals Widespread Noncanonical MicroRNA Targeting
Loeb, G. B., Khan, A. A., Canner, D., Hiatt, J. B., Shendure, J., Darnell, R. B., Leslie, C. S., & Rudensky, A. Y. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.10.002 · Cited by 311
Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix
Reshetnyak, Y. K., Andreev, O. A., Lehnert, U., & Engelman, D. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601463103 · Cited by 257
Self-citationEfficient inhibition of miR-155 function in vivo by peptide nucleic acids
Fabani, M. M., Abreu-Goodger, C., Williams, D., Lyons, P. A., Torres, A. G., Smith, K. G. C., Enright, A. J., Gait, M. J., & Vigorito, E. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq160 · Cited by 214
Sahu, B., Sacui, I., Rapireddy, S., Zanotti, K. J., Bahal, R., Armitage, B. A., & Ly, D. H. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo200482d · Cited by 189
Self-citationLNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.
Zhang, Y., Roccaro, A., Rombaoa, C., Flores, L., Obad, S., Fernandes, S., Sacco, A., Liu, Y., Ngo, H., Quang, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410647 · Cited by 144
Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma
Rai, D., Karanti, S., Jung, I., Dahia, P. L. M., & Aguiar, R. C. T. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.10.008 · Cited by 142
Rather, M. I., Nagashri, M. N., Swamy, S. S., Gopinath, K. S., & Kumar, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.425736 · Cited by 127
Measuring Tumor Aggressiveness and Targeting Metastatic Lesions with Fluorescent pHLIP
Reshetnyak, Y. K., Yao, L., Zheng, S., Kuznetsov, S., Engelman, D. M., & Andreev, O. A. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0457-z · Cited by 118
Self-citationpHLIP-Mediated Translocation of Membrane-Impermeable Molecules into Cells
Thévenin, D., An, M., & Engelman, D. M. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.06.006 · Cited by 93
Self-citationOvercoming biological barriers to in vivo efficacy of antisense oligonucleotides
White, P. J., Anastasopoulos, F., Pouton, C. W., & Boyd, B. J. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001021 · Cited by 91
Li, S., Chen, T., Zhong, Z., Wang, Y., Li, Y., & Zhao, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.779 · Cited by 86
The Duality of OncomiR Addiction in the Maintenance and Treatment of Cancer
Cheng, C. J., & Slack, F. J. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318258b75b · Cited by 64
Self-citationBrognara, E., Fabbri, E., Bazzoli, E., Montagner, G., Ghimenton, C., Eccher, A., Cantù, C., Manicardi, A., Bianchi, N., Finotti, A., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1405-6 · Cited by 64
Nielsen, P. E., & Shiraishi, T. (2011) · Artificial DNA PNA & XNA · doi:10.4161/adna.18739 · Cited by 61
Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq
Xu, G., Fewell, C., Taylor, C. M., Deng, N., Hedges, D. J., Wang, X., Zhang, K., Lacey, M. R., Zhang, H., Yin, Q., et al. (2010) · RNA · doi:10.1261/rna.2194910 · Cited by 61
Nielsen, P. E. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46864-6_114 · Cited by 56
Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Cheng, C., Saltzman, W. M., & Slack, F. J. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320290004 · Cited by 51
Self-citationMicro-RNA Expression and Function in Lymphomas
Sandhu, S. K., Croce, C. M., & Garzon, R. (2011) · Advances in Hematology · doi:10.1155/2011/347137 · Cited by 42
miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs.
Fabbri, E., Brognara, E., Borgatti, M., Lampronti, I., Finotti, A., Bianchi, N., Sforza, S., Tedeschi, T., Manicardi, A., Marchelli, R., et al. (2011) · Epigenomics · doi:10.2217/epi.11.90 · Cited by 41
Wang, Y.-Z., Ff, T., Yan, M., Zhang, J.-M., Liu, Q., Lu, J.-Y., Zhou, W.-B., Yang, H., & Li, J. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12265 · Cited by 37
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Non-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884
Self-citationThe role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Self-citationLu, Y., Aimetti, A. A., Langer, R., & Gu, Z. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.75 · Cited by 1,421
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 975
Metadata
- Authors
- Cheng, C. J., Bahal, R., Babar, I. A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D. T., Glazer, P. M., Engelman, D. M., Saltzman, W. M., & Slack, F. J.
- Venue
- Nature
- Published
- 2014-11-17
- Volume
- 518
- Issue
- 7537
- Pages
- 107-110
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2042968293
- Cited by
- 823
- References
- 39
- FWCI
- 30.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.